OncoSec Announces Preclinical Data Demonstrating Multi-Gene Expression Platform for Delivery of Multiple Cancer Immunotherapies at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2017

SAN DIEGO, Nov. 9, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ:ONCS), a company developing DNA-based cancer immunotherapies, will present emerging data from its novel, multi-gene expression platform termed Polycistronic Interleukin-12 Immune Modulator (PIIM). The poster presentation entitled: "Intratumoral administration of a multigene construct by electroporation can effectively modulate anti-tumor response in a murine B16.F10 model" (P403) will be presented during the "Oncolytic Viruses and Intratumoral Therapies" session on Friday, November 10^th at 12:30-2:00 p.m and 6:30-8:00 p.m. ET at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2017, in National Harbor, MD.

The PIIM platform builds upon OncoSec's existing plasmid-based cancer immunotherapy platform and may offer both enhanced therapeutic activity as well as manufacturing efficiencies. Preclinical data demonstrate the novel platform's flexibility to add multiple immune modulating genes to alter the tumor microenvironment which, when combined with electroporation in a preclinical tumor animal model, resulted in regression of tumor growth in both the treated primary lesion and a distant untreated lesion.

"Immunotherapy has transformed the treatment of multiple cancers, including melanoma; however, current agents do not help all patients or have toxic side effects preventing broader use or in combination with other agents," said Dan O'Connor, CEO of OncoSec. "The ability to enhance response with a simultaneous and potentially safe combination therapy, including cytokines, checkpoint modulators, and antibodies, allows the immune system to better recognize and attack the tumor, an advantage of the PIIM platform versus other products currently under development."

The full abstract is available and can be viewed on the STIC website at www.sitcancer.org. The presentation is available in the Publications section of OncoSec's website.

About the SITC Annual Meeting
The Society for Immunotherapy of Cancer (SITC) is a non-profit medical professional society of influential scientists, academicians, researchers, clinicians, government representatives, and industry leaders from around the world dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy.  Currently, SITC has nearly 1,600 members representing 17 medical specialties and are engaged in research and treatment of at least a dozen types of cancer. The 32nd SITC Annual Meeting & Associated Programs will take place November 8-12, 2017 at the Gaylord National Hotel & Convention Center in National Harbor, MD. For more information, please go to http://www.sitcancer.org/2017.

About Polycistronic Interleukin-12 Immune Modulator (PIIM)
PIIM represents an advancement for OncoSec's plasmid-based cancer immunotherapy platform, coupling improved in vivo electroporation with the ability to combine multiple therapeutic molecules in a single DNA plasmid. The PIIM technology platform offers expedited design and molecular cloning of these molecules, individually or fused, with tailored effector functions and relative expression levels. Delivery of multifunctional combinations from a single plasmid backbone may also simplify the manufacturing process.

About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse^®, for the treatment of cancer. ImmunoPulse is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12 (tavokinogene telseplasmid [pIL-12] or "tavo"). In Phase 1 and 2 clinical trials, ImmunoPulse^® IL-12 has demonstrated a favorable safety profile, evidence of anti-tumor activity in the treatment of various solid tumors, and the potential to reach beyond the site of local treatment to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse IL-12, is currently in clinical development for metastatic melanoma and triple-negative breast cancer. The program's current focus is on the significant unmet medical need in patients with melanoma who are refractory or have relapsed on anti-PD-1 therapies. In addition to tavo, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse platform. For more information, please visit www.oncosec.com.

OncoSec Medical Incorporated Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements about OncoSec's business strategies, including advancement of its lead melanoma program and its broader clinical portfolio and plans to pursue collaborations with industry partners, as well as the potential contributions and impact of new directors on these strategies. In some cases, you can identify forward-looking statements by terminology such as "may", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "potential" or "continue" or the negative of these terms or other comparable terminology.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on management's current preliminary expectations and are subject to risks and uncertainties, which may cause OncoSec's results to differ materially and adversely from the statements contained herein. Potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, the following: the status, progress and results of clinical programs; ability to obtain regulatory approvals for, and the level of market opportunity for, OncoSec's product candidates; OncoSec's business plans, strategies and objectives, including plans to pursue collaboration, licensing or other similar arrangements or transactions; expectations regarding OncoSec's liquidity and performance, including expense levels, sources of capital and ability to maintain operations as a going concern; the competitive landscape of OncoSec's industry; and general market, economic and political conditions; and the other factors discussed in OncoSec's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended July 31, 2017.

Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Media Relations
OncoSec Medical Incorporated
[email protected]
855.662.6732

Investor Relations
OncoSec Medical Incorporated
[email protected]
855.662.6732

Business Development
OncoSec Medical Incorporated
[email protected]

SOURCE OncoSec Medical Incorporated

Related Links

http://www.oncosec.com